1. Home
  2. ADIL vs DRMA Comparison

ADIL vs DRMA Comparison

Compare ADIL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals Inc

HOLD

Current Price

$2.79

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.30

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADIL
DRMA
Founded
2010
2014
Country
United States
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
5.1M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
ADIL
DRMA
Price
$2.79
$1.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$37.50
$10.00
AVG Volume (30 Days)
86.6K
94.6K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$0.64
52 Week High
$5.17
$7.33

Technical Indicators

Market Signals
Indicator
ADIL
DRMA
Relative Strength Index (RSI) 55.00 49.23
Support Level $1.59 $1.13
Resistance Level $2.98 $1.40
Average True Range (ATR) 0.20 0.12
MACD -0.03 -0.01
Stochastic Oscillator 57.69 17.89

Price Performance

Historical Comparison
ADIL
DRMA

About ADIL Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: